Join Our Team

Tr1X is building a diverse, bold, agile and collaborative organization. Join us to work with leading experts in the field and bring novel, life-changing therapies to patients.

Our background

Tr1X (pr. “Trix”) is a biotechnology company focused on engineering cures for autoimmune and inflammatory diseases. We develop cellular therapies with the potential to cure disease by inducing immune tolerance and restoring homeostasis. Tr1X has a state-of-the-art technology platform that allows for the scalable generation of engineered living drugs to help patients suffering from debilitating diseases with high unmet medical need.

Our values

At Tr1X, our unwavering dedication to patients, science and one another is driven by our profound desire to effect real change. We pursue excellence by upholding the highest standards through meticulous attention to detail and cultivation of expert knowledge. We empower our team by crafting and celebrating a culture where creative problem-solving and bold decision making thrive, supported by a foundation of transparency, trust, and respect. We embrace collaboration by creating a cohesive environment that elevates communication, supports growth, recognizes achievements and fosters collective enthusiasm.

Our benefits

In addition to a competitive compensation package with stock options, Tr1X offers comprehensive benefits for our employees  and their families including:

Medical insurance

Dental insurance

Vision insurance

Company-sponsored  life & AD&D insurance

Company sponsored
short-term and  long-term disability insurance

401(k) with
employer match

Paid Time Off

Optional additional  life insurance

Publications

Peer-reviewed & evidence-based science. It’s what we do.

Publications

Cellular immunotherapies and immune cell depleting therapies in inflammatory bowel diseases: the next magic bullet?

View Article

Press Release

Tr1X to Participate at Upcoming Healthcare Investment Conferences

View Article

Press Release

Tr1X Announces FDA Clearance of IND Application for TRX103, an Allogeneic Engineered Tr1 Treg Cell Therapy for Treatment-Refractory Crohn’s Disease.

View Article

Press Release

Tr1X, Inc. Announces $75 Million Series A Financing to Develop Best-in-Class Universal Allogeneic Regulatory T (Treg) and CAR-Treg Cell Therapies to Treat and Potentially Cure Autoimmune and Inflammatory Diseases

View Article

Press Release

Tr1X Announces FDA Clearance of First Investigational New Drug Application for TRX103, an Allogeneic Regulatory T-Cell Therapy to Treat Autoimmune Diseases

View Article

Press Release

Tr1X Announces First Patient Dosed in Proof of Concept GvHD Trial Evaluating TRX103, a First-in-Class Type 1 Treg (Tr1) Cell Therapy

View Article

Interview

Graphite Bio co-founder debuts Treg cell therapy startup with $75M, aims to ‘trick’ immune system into resetting

View Article

Publications

Opportunities for Treg cell therapy for the treatment of human disease

View Article

Current job openings

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

At Tr1X we believe that a diverse, open, and inclusive environment and culture is key to our success. Tr1X will not be influenced in recruitment, hiring, promotion or any other employment practices by race, color, citizenship status, national origin, ancestry, sex, sexual orientation, gender identity/expression, age, religion, physical or mental disability, medical or genetic condition, marital status, veteran status, or any other characteristics protected under applicable federal, state and local laws. Tr1X will make reasonable accommodations for qualified individuals with known disabilities, in accordance with applicable laws.